Company
Radiopharmaceutical Specialists. The CPDC was founded by Dr
John Valliant of McMaster University in 2008 as a Centre of
Excellence for Commercialization and Research (CECR),
specializing in radiopharmaceutical research and development.
CPDC is focused on the discovery, development, and clinical
translation of diagnostic and therapeutic radiopharmaceuticals
across Canada.
Radiopharmaceutical Specialists. The CPDC was founded by Dr
John Valliant of McMaster University in 2008 as a Centre of
Excellence for Commercialization and Research (CECR),
specializing in radiopharmaceutical research and development.
CPDC is focused on the discovery, development, and clinical
translation of diagnostic and therapeutic radiopharmaceuticals
across Canada.
John Valliant of McMaster University in 2008 as a Centre of
Excellence for Commercialization and Research (CECR),
specializing in radiopharmaceutical research and development.
CPDC is focused on the discovery, development, and clinical
translation of diagnostic and therapeutic radiopharmaceuticals
across Canada.
CPDC has been integral
to the growth of the radiopharmaceutical ecosystem in Canada
CPDC has brought over a dozen radiopharmaceuticals into clinical development, which currently supports more than 25 clinical trialsin Canada, North America and Europe
CPDC has successfully incubated, grown, and spun-out two Canadian-based radiopharmaceutical companies: Fusion Pharmaceutical Inc., and AtomVie Global Radiopharma.
Between CPDC and its joint-venture CanProbe, the centres have provided 65,000 clinical doses to patients in Canada for a variety of diseases.
